Pfizer and Stemgent to collaborate on stem cell research
16 April 2010 00:00 in Pharmaceutical Company Product News
Pfizer has entered into collaboration with stem cell science specialist Stemgent in a partnership designed to aid pharmaceutical research efforts.
The agreement will see Stemgent distribute research reagents developed by Pfizer with pharmaceutical modes of action sold to scientists in order to conduct experiments.
It will also see Pfizer and Stemgent collaborate to conduct an ongoing review of the partnership's progress, including information monitoring, materials exchange and providing research guidance.
Pfizer expressed hope that this new agreement will assist stem cell research into a variety of medical fields, such as cancer treatment, metabolic disease and neuroscience.
Dr Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, said: "We are pleased to form this partnership with Stemgent. We applaud the efforts Stemgent has made in bringing important research tools to the stem cell community."
Earlier this month, the firm entered into collaboration with MicuRx Pharmaceuticals and Cumencor Pharmaceuticals to develop a number of new tuberculosis treatments.
Other news stories from 16/04/2010
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency